Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02778399 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
A Phase 2 study, sponsored by ObsEva.
- Completed
- Registry status
- Phase 2
- Development phase
- 328
- Enrollment target
NCT02778399 is a Phase 2 study that has completed, run by ObsEva. The registered enrollment target is 328 participants.
The verdict
NCT02778399, a Phase 2 study, has completed, sponsored by ObsEva.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 328 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
Interventions
- DRUG Placebo
- DRUG OBE2109
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02778399
The ClinicalTrials.gov registry entry for NCT02778399 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ObsEva, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02778399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02778399 about?
NCT02778399 is a clinical study titled "A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis". The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
What is the current status of trial NCT02778399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 328 participants. The study started on 2016-07. Estimated completion is 2019-07-01.
What interventions are being tested in trial NCT02778399?
The interventions under investigation include: Placebo (DRUG), OBE2109 (DRUG).
Who is sponsoring clinical trial NCT02778399?
This trial is sponsored by ObsEva, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.